Methods We searched in four databases (PubMed, Embase, Cochrane Library, and Web of Science) from inception to 1 November 2022 (updated on March 20, 2023) for potentially relevant records without language restrictions
Several potential risks arise from concurrent cannabis and Wegovy use, though robust clinical trial data specifically examining this combination are currently unavailable: Reduced treatment efficacy : The most significant concern is that cannabis-induced appetite stimulation may counteract Wegovy's appetite-suppressing effects, potentially compromising weight loss outcomes
In fact, a recent study found adverse effects were one of the most frequent reasons for discontinuation of GLP-1s
Examples include liraglutide (LEAN Project: ClinicalTrials.gov, number NCT01237119) [7] and semaglutide (ClinicalTrials.gov, number NCT02970942) [8], both of which have completed phase II trials, meeting their primary endpoint of NASH resolution without worsening fibrosis
Its prevalence is still rising steadily, which constitutes a substantial health burden to society
Body weight reductions with oral semaglutide 14 mg and flexibly dosed varied slightly across background medication subgroups within each trial, but with no significant treatment interactions by background medication (Fig
